| Novartis Pharma Schweiz AG - Exelon Patch 15, transdermales Pflaster |
| 58078 | | 05 | | Exelon Patch 15 | | transdermales Pflaster | | N06DA03 | | Rivastigmin | | 22.05.2013 | | |
|
| Composition |
| rivastigminum 27 mg, butylis methacrylatis et methylis methacrylatis polymerisatum, acrylic adhesive, int-rac-alpha-tocopherolum, silicone adhesive, dimeticonum, Trägermaterial: poly(ethylenis terephthalas), Drucktinte (Beige): ad praeparationem pro 15 cm², cum liberatione 13.3 mg/24h. |
| Packungsbestandteile |
| Transdermales Pflaster | | | | | Principe actif | Concentr. |
|---|
| Rivastigminum | 27 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Rivastigminum | 27 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Acrylic Adhesive | | | | Butylis Methacrylatis | | | | Cum Liberatione | 13.3mg / 24h | | | Dimeticonum | | | | Drucktinte (Beige): ad Praeparationem | 15 cm | | | Int-Rac-Alpha-Tocopherolum | | | | Methylis Methacrylatis Polymerisatum | | | | Poly(Ethylenis Terephthalas) | | Trägermaterial | | Silicone Adhesive | | |
| |
|
|
